Evidence map›Paper›PMID 40023825›Full record

ArticleEmerging infectious diseases2025

Evaluation of High-Dose Isoniazid in Multidrug-Resistant Tuberculosis Treatment.

Valentina Gerussi, Tania Petersen, Isabelle Bonnet, Alexandra Aubry, Marwa Bachir, Esther Gyde, Florence Morel, Corentin Poignon, Brigitte Rached, Valérie Pourcher and 5 more

Abstract read
In one paragraph

Article in Emerging infectious diseases, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

15 authors.

Valentina Gerussi
Tania Petersen
Isabelle Bonnet
Alexandra Aubry
Marwa Bachir
Esther Gyde
Florence Morel
Corentin Poignon
Brigitte Rached
Valérie Pourcher
Christophe Rioux
Dorothée Vallois
Nicolas Veziris
Jérôme Robert
Lorenzo Guglielmetti

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

High-dose isoniazid is recommended to treat multidrug-resistant tuberculosis (MDR TB). Among 958 MDR TB isolates identified in France during 2008-2022, 93.1% exhibited high-level isoniazid resistance, and molecular testing showed limited diagnostic accuracy in predicting resistance. Clinicians should reconsider using high-dose isoniazid in MDR TB treatment because of suboptimal effect and toxicity concerns.

Indexed as

Antitubercular AgentsIsoniazidMycobacterium tuberculosisTuberculosis, Multidrug-ResistantAdultDrug Resistance, Multiple, BacterialFemaleFranceHumansMaleMicrobial Sensitivity TestsMiddle AgedAntitubercular AgentsIsoniazidantimicrobial resistancebacteriadrug susceptibility testinggenotypichepatotoxicityinhAisoniazidkatGMDR TBmutationphenotypicrespiratory infectionsSCRtuberculosis and other mycobacteria

Identifiers

PMID40023825
PMCPMC11878312

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.